Jan 09, 2020
Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs Market
Nov 15, 2019
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
Nov 11, 2019
Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965
Oct 21, 2019
Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
May 22, 2019
Prometic presents new PBI-4050 and Ryplazim(TM) (plasminogen) data on lung fibrosis at the 2019 ATS Conference
May 20, 2019
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
May 19, 2019
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
Apr 18, 2019
Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
Mar 04, 2019
Biotechs Search for Innovative Methods to Combat Common Diseases
Feb 27, 2019
Biotechnology Companies Ramp up Funding as Deadly Diseases Come Into the Spotlight
Jan 16, 2019
Bridge Biotherapeutics Announces FDA Orphan Drug Designation for BBT-877 in Idiopathic Pulmonary Fibrosis (IPF)
Dec 16, 2018
Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF
Nov 18, 2018
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-877, an Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis
Aug 22, 2018
Bridge Biotherapeutics Presented Preclinical Study Results on BBT-877, an Autotaxin inhibitor at the IPF Summit 2018
May 22, 2018
Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis
May 22, 2018
Pliant Therapeutics Presents Idiopathic Pulmonary Fibrosis Biomarker Discovery Research at American Thoracic Society 2018 International Conference
Jan 29, 2018
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Dec 15, 2017
Global Anti-idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027
Nov 02, 2017
Idiopathic Pulmonary Fibrosis Market - Global Opportunity Analysis and Industry Forecast, 2017-2023
Oct 12, 2017
Global Idiopathic Pulmonary Fibrosis Market Expected to Reach $3,569 Million by 2023 - Allied Market Research